BAFF and IL-7 Adjuvant for HIV-1 MPER Tolerance Break
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and immunization strategies fail to induce robust antibody responses against the membrane proximal external region (MPER) of HIV-1, as MPER-reactive B cells are tolerized during development, leading to impaired immune responses due to self-reactivity and peripheral tolerance mechanisms.
Innovation Solution
Administration of BAFF and IL-7 as an adjuvant with HIV-1 immunogens to break peripheral tolerance and anergy, allowing the production of broadly neutralizing antibodies by promoting the development of naïve B cells and their intermediate clones that secrete anti-HIV-1 antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines and immunization strategies are used to target HIV-1 MPER, then antibody responses are elicited, but the responses are non-neutralizing and impaired due to peripheral tolerance mechanisms
Solution Approach 1:
The patent converts the harmful effect of peripheral tolerance (which normally suppresses self-reactive B cells) into a beneficial outcome by using tolerized B cells as a source for generating neutralizing antibodies. The method involves isolating B cells from tolerant individuals, expanding them in vitro, and reinfusing them to overcome the tolerance suppression and generate protective immune responses.
Solution Approach 2:
The patent introduces an intermediary system (in vitro expansion culture) that mediates between the tolerized B cells and the desired neutralizing antibody response. The culture system allows B cells to be expanded and activated outside the body, bypassing the peripheral tolerance mechanisms that would normally prevent their activation, and then reinfused to generate protective immunity.
2Object-affected harmful factors
If B cells are tolerized during development to maintain self-tolerance, then autoimmune reactions are prevented, but MPER-reactive B cells are purged leading to impaired vaccine responses
Solution Approach 1:
The patent segments the immune response process into distinct phases: (1) maintenance of peripheral tolerance in vivo to prevent autoimmunity, (2) in vitro expansion and activation of tolerized B cells to generate neutralizing antibodies, and (3) reinfusion to establish protective immunity. This segmentation allows simultaneous achievement of both self-tolerance and effective vaccine response.
Solution Approach 2:
The in vitro expansion culture acts as an intermediary that temporarily removes B cells from the constraints of peripheral tolerance mechanisms. During this intermediate step, B cells can be activated and expanded without the suppressive effects of tolerance, then reinfused to generate protective responses without causing autoimmunity.
3Reliability
If MPER-specific B cells are expanded in vitro and reinfused, then neutralizing antibody responses are enhanced, but the complexity of the immunization strategy increases
Solution Approach 1:
The patent employs self-service mechanisms where the patient's own tolerized B cells are harvested, expanded in vitro, and reinfused to generate protective immunity. This autologous approach leverages the patient's own immune system resources, reducing the need for complex external adjuvants or multiple vaccine formulations while achieving enhanced neutralizing antibody responses.
Solution Approach 2:
The patent changes key parameters of the immune response by manipulating B cell expansion conditions in vitro (culture duration, cytokine concentrations, activation signals) to optimize the generation of neutralizing antibodies. These parameter changes enable control over the quality and quantity of the immune response while managing the overall complexity of the strategy.
Data Source
AI summary
The present invention relates, in general, to human immunodeficiency virus (HIV-1) and, in particular, to a method of enhancing an immune response to an HIV-1 immunogen, and to compounds and compositions suitable for use in such a method.